Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1

Hepatology

Volumn 53, Issue 4, 2011, Pages 1109-1117

  Sievert, William ^a   Dore, Gregory J ^b,c   Mccaughan, Geoffrey W ^d   Yoshihara, Motoko ^e   Crawford, Darrell H ^f   Cheng, Wendy ^g   Weltman, Martin ^h   Rawlinson, William ⁱ   Rizkalla, Bishoy ^e   Depamphilis, Jean K ^j   Roberts, Stuart K ^k  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e Roche Products   (Australia)

^f GREENSLOPES PRIVATE HOSPITAL   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h NEPEAN HOSPITAL   (Australia)

ⁱ New South Wales Government   (Australia)

^j HOFFMANN LA ROCHE INC   (United States)

^k ALFRED HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; SERUM ALBUMIN; VIRUS RNA;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79953738444     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24180     Document Type: Article

References (13)

1. Mac Nicholas R, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV-the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 2010; 31: 929-937.
2. Sulkowski M, Shiffman M, Afdhal N, Reddy K, McCone J, Lee W, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139: 1602-1611.
3. Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. HEPATOLOGY 2009; 50: 1045-1055.
4. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996; 24: 289-293.
5. Sulkowski M, Wasserman R, Brooks L, Ball L and R Gish. Changes in hemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-250.
6. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, et al. Factors contributing to ribavirin induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-1317.
7. Russmann S, Grattagliano I, Portincasa P, Palmieri V, Palasciano G. Ribavirin induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13: 3351-3357.
8. Tod M, Farcy-Afif M, Stocco J, Boyer N, Bouton V, Sinegre M, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin induced anemia in chronic hepatitis C. Clin Pharmacokinet 2005; 44: 417-428.
9. Bruchfeld A, Lindahl K, Schwarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
10. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62: 710-714.
11. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2009; 464: 405-408.
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
13. Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53: 616-623.